<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255462</url>
  </required_header>
  <id_info>
    <org_study_id>CLFG316A2102</org_study_id>
    <nct_id>NCT01255462</nct_id>
  </id_info>
  <brief_title>Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration</brief_title>
  <official_title>A Multicenter, Open Label, Single Ascending Dose Study to Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal
      LFG316 in patients with advanced age-related macular degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of single intravitreal doses of LFG316 in patients with advanced age-related macular degeneration.</measure>
    <time_frame>Day 1 to Day 85 (starting from the day of intravitreal injection until the end of the study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the serum pharmacokinetic profile of single intravitreal doses of LFG316 in patients with advanced age-related macular degeneration.</measure>
    <time_frame>Day 1 to Day 85 (starting from the day of intravitreal injection until the end of the study)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Advanced Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>LFG316 0.15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LFG316 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LFG316 1.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LFG316 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LFG316</intervention_name>
    <arm_group_label>LFG316 0.15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LFG316</intervention_name>
    <arm_group_label>LFG316 0.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LFG316</intervention_name>
    <arm_group_label>LFG316 1.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LFG316</intervention_name>
    <arm_group_label>LFG316 5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female AMD patients 55 to 90 years old, inclusive. In either eye, diagnosis of
             geographic atrophy or choroidal neovascularization due to AMD

          -  ETDRS best corrected visual acuity of 60 letters or worse in the study eye.

        Exclusion Criteria:

          -  Retinal disease other than AMD in study eye which, in the investigator's opinion, may
             pose a safety risk or interfere with the study.

          -  Choroidal neovascularization due to a cause other than AMD.

          -  In the study eye, media opacity that interferes with fundus imaging or is likely to
             require surgery during the study period.

          -  Any of the following treatments to the study eye within 14 days prior to dosing:
             ranibizumab (Lucentis), bevacizumab (Avastin), pegaptanib (Macugen), or other VEGF
             inhibitor; OR likely requirement for one of the above treatments within 14 days of
             LFG316 administration.

          -  Any of the following within 30 days prior to dosing: photodynamic therapy treatment in
             the study eye; extrafoveal or juxtafoveal thermal laser photocoagulation in the study
             eye; systemic or topical (ophthalmic) steroid use in the study eye; bacterial
             keratitis in the study eye; OR intraocular surgery (including cataract surgery) in the
             fellow eye.

          -  Any of the following within 90 days prior to dosing: intraocular surgery (including
             cataract surgery) in the study eye; OR intravitreal or periocular corticosteroid
             injection in the study eye.

          -  Participation in another interventional clinical study, or use of any experimental
             treatment for AMD or any other investigational new drug within 12 weeks prior to the
             start of study treatment. Clinical trials solely involving over-the-counter vitamins,
             supplements, or diets will not exclude the patients from study participation.

          -  Any medical condition likely to interfere with the patient's participation in the
             study, or likely to cause serious adverse events during the study.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona,</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group,</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Ophthalmic Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Opthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, Nose and Throat Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <last_update_submitted>April 30, 2012</last_update_submitted>
  <last_update_submitted_qc>April 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD,</keyword>
  <keyword>ARMD,</keyword>
  <keyword>Age-related Macular Degeneration,</keyword>
  <keyword>Eye Disease,</keyword>
  <keyword>Wet AMD,</keyword>
  <keyword>Neovascular AMD,</keyword>
  <keyword>Choroidal Neovascular Membrane,</keyword>
  <keyword>Choroidal Neovascularization,</keyword>
  <keyword>Drusen,</keyword>
  <keyword>Geographic Atrophy,</keyword>
  <keyword>Complement,</keyword>
  <keyword>C5,</keyword>
  <keyword>Antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

